StocksFundsScreenerSectorsWatchlists
IKNA

IKNA - Ikena Oncology, Inc. Stock Price, Fair Value and News

1.43USD+0.04 (+2.88%)Delayed as of 28 Mar 2024, 12:01 pm ET

Market Summary

IKNA
USD1.43+0.04
Delayedas of 28 Mar 2024, 12:01 pm
2.88%

IKNA Stock Price

View Fullscreen

IKNA RSI Chart

IKNA Valuation

Market Cap

67.1M

Price/Earnings (Trailing)

-0.98

Price/Sales (Trailing)

7.32

Price/Free Cashflow

-0.84

IKNA Price/Sales (Trailing)

IKNA Profitability

Return on Equity

-40.16%

Return on Assets

-35.49%

Free Cashflow Yield

-119.5%

IKNA Fundamentals

IKNA Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-87.92%

Rev. Growth (Qtr)

-44.43%

IKNA Earnings

Earnings (TTM)

-68.2M

Earnings Growth (Yr)

-38.25%

Earnings Growth (Qtr)

-12.37%

Breaking Down IKNA Revenue

52 Week Range

1.407.64
(Low)(High)

Last 7 days

-5.7%

Last 30 days

8.0%

Last 90 days

-34.5%

Trailing 12 Months

-65.2%

How does IKNA drawdown profile look like?

IKNA Financial Health

Current Ratio

12.58

IKNA Investor Care

Shares Dilution (1Y)

33.10%

Diluted EPS (TTM)

-1.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202317.5M19.2M14.0M9.2M
202230.9M27.7M30.4M15.6M
20219.4M9.9M10.8M31.0M
20200009.2M

Tracking the Latest Insider Buys and Sells of Ikena Oncology, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 04, 2023
bonita david p
acquired
-
-
153,121
-
Aug 04, 2023
orbimed advisors llc
acquired
-
-
153,121
-
Jun 24, 2022
bonita david p
bought
-803,975
4.96281
-162,000
-
Jun 24, 2022
orbimed advisors llc
bought
-803,975
4.96281
-162,000
-
Jun 23, 2022
orbimed advisors llc
bought
-86,884
3.71
-23,419
-
Jun 23, 2022
bonita david p
bought
-86,884
3.71
-23,419
-
Jun 22, 2022
orbimed advisors llc
bought
-237,161
3.55
-66,806
-
Jun 22, 2022
bonita david p
bought
-237,161
3.55
-66,806
-

1–10 of 41

Which funds bought or sold IKNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
12.7
-2,854,470
3,003,950
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
120
350
92,964
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
24.14
-23,356
30,310
-%
Feb 26, 2024
Virtu Financial LLC
added
130
2,000
53,000
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-4,826
4,029
-%
Feb 15, 2024
BARCLAYS PLC
added
18.45
-411,000
483,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
sold off
-100
-217
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
43,482
43,482
-%
Feb 15, 2024
Blue Owl Capital Holdings LP
new
-
3,848,620
3,848,620
0.92%
Feb 14, 2024
ORBIMED ADVISORS LLC
added
11.09
-6,823,560
6,972,540
0.14%

1–10 of 50

Are Funds Buying or Selling IKNA?

Are funds buying IKNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IKNA
No. of Funds

Unveiling Ikena Oncology, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.1%
2,469,828
SC 13G/A
Feb 14, 2024
omega fund vi, l.p.
4.7%
2,249,123
SC 13G/A
Feb 14, 2024
citadel advisors llc
0.3%
6
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Oct 19, 2023
gilead sciences, inc.
6.7%
2,931,467
SC 13G
Sep 21, 2023
orbimed advisors llc
5.2%
2,189,111
SC 13D/A
Sep 14, 2023
orbimed advisors llc
5.5%
2,342,232
SC 13D/A
Feb 14, 2023
biotechnology value fund l p
3.8%
1,358,593
SC 13G/A
Feb 14, 2023
citadel advisors llc
5.9%
6
SC 13G/A

Recent SEC filings of Ikena Oncology, Inc.

View All Filings
Date Filed Form Type Document
Mar 12, 2024
S-8
Employee Benefits Plan
Mar 12, 2024
10-K
Annual Report
Mar 11, 2024
SC 13G/A
Major Ownership Report
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
3
Insider Trading
Feb 21, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Ikena Oncology, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Ikena Oncology, Inc. News

Latest updates
InvestorsObserver • 20 Mar 2024 • 01:13 pm
Yahoo Movies Canada • 18 Mar 2024 • 06:50 pm
MarketBeat • 16 Mar 2024 • 07:00 am
Simply Wall St • 14 Mar 2024 • 01:45 pm
InvestorsObserver • 28 Feb 2024 • 08:00 am
CNN • 2 months ago

Ikena Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue-44.4%1.001.002.005.005.006.000.003.0020.004.004.003.000.003.003.003.00
Operating Expenses9.1%23.0021.0020.0021.0021.0024.0021.0020.0017.0018.0016.0013.0026.009.008.0010.00
  S&GA Expenses37.4%8.006.005.005.005.005.006.006.005.005.005.003.003.002.002.003.00
  R&D Expenses-2.6%14.0015.0015.0016.0016.0019.0015.0014.0012.0013.0011.0010.0023.007.006.008.00
Net Income-12.4%-19.49-17.34-17.11-14.22-14.10-17.34-20.49-16.843.00-14.51-12.68-9.72-26.05-6.22-5.04-6.94
Net Income Margin-65.4%-7.44*-4.50*-3.27*-3.77*-4.40*-1.71*-1.77*-1.33*-1.10*-5.81*-5.51*-4.98*----
Free Cashflow-10.4%-22.08-20.00-18.14-19.94-17.89-18.35-19.49-19.82-13.92-18.17-15.91-14.01----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-10.8%192215172152172190211228248262279294168
  Current Assets-11.0%179201161141160178199216237252269283166
    Cash Equivalents-0.1%12112171.0029.0060.0067.0048.0047.00233246264281163
  Net PPE-11.3%2.003.003.003.003.003.003.002.002.002.002.002.001.00
Liabilities-20.6%22.0028.0015.0017.0025.0032.0037.0035.0040.0058.0063.0066.0063.00
  Current Liabilities-26.3%14.0019.0012.0014.0022.0025.0029.0025.0027.0031.0031.0030.0028.00
Shareholder's Equity9.3%170155157135147159174193208203216228-
  Retained Earnings-7.4%-282-262-245-228-214-200-182-162-145-148-133-121-111
  Additional Paid-In Capital8.0%45241840336436236035835635335135034910.00
Shares Outstanding9.4%48.0044.0042.0036.0036.0036.0036.0036.0036.0025.0036.004.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-9.1%-21,819-19,997-18,143-19,784-17,655-17,219-19,451-19,784-13,368-17,990-15,724-13,170-12,570-7,670-7,712-9,874
  Share Based Compensation-12.2%1,7551,9981,8792,0001,8591,8111,9551,9001,5811,4491,262885650418354375
Cashflow From Investing-36.1%20,37631,89422,680-10,80610,49935,78220,486-166,051-550-184-187-8393,038-1.00-117
Cashflow From Financing-99.8%60.0038,918--1.0024.0057549523669.00-1,095132,528116,163--21.00
  Buy Backs---663-------------

IKNA Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue  
Research and development revenue under collaboration agreement$ 9,160$ 15,618
Revenue from Contract with Customer, Product and Service [Extensible List]us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:InProcessResearchAndDevelopmentMember
Operating expenses  
Research and development$ 59,652$ 64,321
General and administrative24,92522,201
Total operating expenses84,57786,522
Loss from operations(75,417)(70,904)
Other income (expense)  
Investment income7,1112,149
Other expense(22)(10)
Total other income, net7,0892,139
Loss before income taxes(68,328)(68,765)
Income tax benefit (expense)162 
Net loss(68,166)(68,765)
Other comprehensive loss:  
Unrealized loss on marketable securities715(763)
Total comprehensive loss$ (67,451)$ (69,528)
Net loss per share:  
Net loss per share attributable to common stockholders basic$ (1.63)$ (1.9)
Net loss per share attributable to common stockholders diluted$ (1.63)$ (1.9)
Weighted-average common shares outstanding, basic41,735,08136,188,420
Weighted-average common shares outstanding, diluted41,735,08136,188,420

IKNA Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 119,894$ 59,919
Marketable securities55,57197,028
Prepaid expenses and other current assets3,1973,063
Total current assets178,662160,010
Property and equipment, net2,3353,205
Right-of-use asset5,6865,255
Deposits and other assets5,4093,789
Total assets192,092172,259
Current liabilities:  
Accounts payable2,0662,093
Accrued expenses and other current liabilities8,5818,343
Operating lease liability3,5581,907
Deferred revenue 9,160
Total current liabilities14,20521,503
Long-term portion of operating lease liability7,1803,787
Other long term liabilities950 
Total liabilities22,33525,290
Commitments and contingencies (Note 15)
Stockholders' equity:  
Preferred Stock, $0.001 par value, 10,000,000 shares authorized as of December 31,2023 and 2022; No shares issued and outstanding as of December 31, 2023 or December 31, 2022
Common stock, $0.001 par value, 150,000,000 shares authorized, 48,258,111 shares issued and outstanding as of December 31, 2023; 150,000,000 shares authorized, 36,257,493 shares issued and outstanding as of December 31, 20224836
Additional paid-in capital452,142361,915
Accumulated other comprehensive loss(48)(763)
Accumulated deficit(282,385)(214,219)
Total stockholders' equity169,757146,969
Total liabilities and stockholders' equity$ 192,092$ 172,259
IKNA
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEikenaoncology.com
 EMPLOYEES59

Ikena Oncology, Inc. Frequently Asked Questions


What is the ticker symbol for Ikena Oncology, Inc.? What does IKNA stand for in stocks?

IKNA is the stock ticker symbol of Ikena Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ikena Oncology, Inc. (IKNA)?

As of Wed Mar 27 2024, market cap of Ikena Oncology, Inc. is 67.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers.

What is the fair value of IKNA stock?

You can check IKNA's fair value in chart for subscribers. The fair value of Ikena Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ikena Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IKNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ikena Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether IKNA is over valued or under valued. Whether Ikena Oncology, Inc. is cheap or expensive depends on the assumptions which impact Ikena Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKNA.

What is Ikena Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, IKNA's PE ratio (Price to Earnings) is -0.98 and Price to Sales (PS) ratio is 7.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKNA PE ratio will change depending on the future growth rate expectations of investors.